Promising combo trial for aggressive breast cancer halted early
NCT ID NCT04108858
First seen Nov 01, 2025 · Last updated May 10, 2026 · Updated 24 times
Summary
This study looked at adding a drug called copanlisib to standard targeted therapy (trastuzumab and pertuzumab) for people with advanced HER2-positive breast cancer that has a specific genetic change (PIK3CA or PTEN mutation). The goal was to see if the combination could shrink tumors or keep them stable longer. Only 2 people enrolled before the trial was stopped, so we don't have clear results on how well it works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANATOMIC STAGE IV BREAST CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Los Angeles County-USC Medical Center
Los Angeles, California, 90033, United States
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
-
UCHealth University of Colorado Hospital
Aurora, Colorado, 80045, United States
-
USC / Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
-
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, 73104, United States
Conditions
Explore the condition pages connected to this study.